Luciana Scalone. Centro di Farmacoeconomia Università degli Studi di Milano. Problem
|
|
- Rosanna Henry
- 6 years ago
- Views:
Transcription
1 Qualità della Vita Legata allo Stato di Salute in Farmacoeconomia Luciana Scalone Centro di Farmacoeconomia Università degli Studi di Milano Problem Needs are unlimited resources are limited Resources allocated (devoted) to an intervention can not be allocated to another one Somebody has to decide which interventions will be financed and the priorities
2 Trends Increase of health care expenditure, incompatible with the increase of GDP (last two decades) REASONS Population ageing Increase of expectacies Modern technologies, more effective and more costly Intercations between these aspects Population ageing Proportion of people aged > 60 years (%) ITALY GERMANY JAPAN FRANCE UK USA
3 Approaches to the problem Rationing vs Rationalising (cost containment) (maximun outcome from available resources) Rationing: Uni-dimensioanl task because the expenditure is the only target variable Ratioanlising: bi-dimensional task because costs are referred to outcomes Economics is study of how societies use scarce resources to produce valuable commodities and distribute them among different people Paul A Samuelson,, Nobel Laureate 1970
4 Economics maximizing utility resources limited applicable to alternative uses Pharmacoeconomics -Economics Pharmacoapplication to the pharmaceutical context of Maximization Utility Resources Scarcity Alternative uses
5 Pharmacoeconomics It is a research method that estimates the costs and the outcomes of medical technologies to compare alternative approaches, at least one concerning drug therapy Key elements COSTS EFFECTS ALTERNATIVES PERSPECTIVE TECHNIQUE TIME HORIZON SENSITIVITY
6 Costs and Effects of an Intervention C E Costs and effects =
7 Costs and Effects Direct Indirect Not medical medical Intangible Alternatives Pharmacological Not Pharmacological No intevention
8 Perspective Third-party payer Services supplyers Patient Society Techniques Cost Effectiveness Analysis (CEA) Cost Minimization Analysis (CMA) Cost Utility Analysis (CUA) Cost Benefit Analysis (CBA)
9 Cost effectiveness analysis (CEA) Clinical parameters Survival LYS/LYG Cost utility analysis (CUA) Quality adjusted life years QALY s
10 Cost benefit analysis (CBA) Possible results + Cost - Effect - Evaluate REFUSE ACCEPT (dominant) Evaluate
11 Techniques Cost-benefit analysis 70s, criticism Cost-effectiveness analysis 80s, life expectancy Cost-utility analysis 90s, quality of life, utilities Cost-benefit analysis going beyond health outcomes Before 70s the tool most commonly used was CBA, but concerns were raised over whether it was ethical and possible to value human life in monetary terms. This led to the adoption of the CEA In 80s an extension of CEA was promoted, to consider not just the quantity of life but also the quality of that life (QALYs). The focus of QALYs was anyway on health outcomes In 90s a debate began concerning the inclusion of non health outcomes (waiting time, location of treatment). This led to the reintroduction of CBA
12 Quality of Life Quality of Life In the past, the most important objective in health care was the recovery from the diseases and the survival
13 Quality of Life As a result of successful technologies, years have been added to the life of individuals As a result of higher life expectancy, the incidence and prevalence of chronic diseases such as cancer, CVD and dementia have been increasing People often live with these conditions for many years Quality of Life People, in general healthier and wealthier than in the past, have higher expectations: they expect more than just being alive So, more people live longer, but perhaps some of them might feel their longer life is not worth living!
14 Definition of Quality of Life (QoL) Definition of Quality of Life (QoL) Difficult. The most widely used definition is the one by the World Health Organization (The WHOQOL Group, 1995): QoL is individuals perception of their position in life in the context of the culture and value systems in which they live and in relation to their goals, expectations, standards, concerns. term incorporating physical health, psychological state, level of indipendence, social relationships
15 Health Related Quality of Life (HRQoL) is The impact of an accident/disease and of the related treatment on involved individuals QoL The interest in measuring QoL in health care has increased in last 2 decades Many instruments have been developed and used
16 Instruments Generic vs Specific Indexes vs profiles Self administered, interview, proxy responders Paper, computer based etc Instruments Generic vs Specific Indexes vs profiles Self administered, interview, proxy responders Paper, computer based etc
17 Instruments Generic vs Specific Generic instruments: evaluate HRQoL as a whole. Appliable to a wide range of different people with different type and severity of diseases, different cultures. Useful for comparinsons and decision-making across different diseases and interventions Specific instruments: have been developed on specific groups. They focus on the phenomenon of interest, can be more sensitive, more acceptable, do not allow comparisons EQ-5D profile
18 EQ-5D VAS Examples of clinical areas where EQ-5D is used
19 Available language versions In which countries EQ-5D is being used?
20 Instruments Generic vs Specific Generic instruments: evaluate HRQoL as a whole. Appliable to a wide range of different people with different type and severity of diseases, different cultures Useful for comparinsons and decision-making across diseases, interventions Specific instruments: have been developed on specific groups. They focus on the phenomenon of interest, can be more sensitive, more acceptable, do not allow comparisons ISSQoL
21 Instruments Indexes vs profiles The index is a number quantifying HRQoL The profile describes HRQoL in their domains Index 100 (perfect health) 80 0 (death)
22 Instruments Indexes vs profiles The index is a number quantifying HRQoL The profile describes HRQoL in their domains
23 EQ-5D profile sev mod sev mod sev mod sev mod sev mod 100% 0.0% 0.0% 1.2% 0.0% 6.3% 1.2% 0.0% 6.5% 1.6% 5.4% 3.2% 21.4% 27.4% 80% 43.5% 43.4% 38.7% 60% 40% 20% 0% 52.4% 67.7% 47.6% 32.3% 93.7% 77.4% Test Chi-quadrato (2X2): 72.6% 55.4% 69.8% 73.8% 19.6% 28.6% 51.2% 58.1% mobility self-care usual activities pain/discomfort anxiety/depression severe problems some problems no problem NS NS COCHE Study, podium presentation at ISPOR, 6-8 November 2005
24 SF COCHE (232) 0 PF RP BP GH VT SA RE MH COCIS (50) Italian male population (999) PF=Physical Functioning, RP=Role-Physical, BP=Bodily Pain, GH=General Health, VT=Vitality/Energy, SF=Social Functioning, RE=Role-Emotional, MH=Mental Health COCHE Study, podium presentation at ISPOR, 6-8 November 2005
25 Instruments Indexes vs profiles The index, if appropriate, can be used in economic evaluations (CUAs) The profile can be more useful in clinical practice Cost utility analysis (CUA) Quality adjusted life years QALY s
26 Utility value 0 death 0,48 0,5 1 Perfect health Computing the QALY 1 year of life With utility level = months of life With perfect health (Utility x years of life) = QALY
27 HRQoL and utility index To be considered in economic evaluations, HRQoL has to be given a value Indicator of that value is the maximum amount of a resource the individual is willing to give up to have higher levels of HRQoL, according to his/her preferences These preferences depend on his/her current health state perception, expectations etc The higher the willingness to give up, the lower the value given to the current HRQoL Instruments to estimate utility VAS (does not consider preferences) Standard Gamble Time Trade Off Discrete Choice Experiment
28 Index 100 (perfect health) 80 0 (death) Standard Gamble Current health state Current Health state Certain Uncertain Total recovery: P Death: 1 - P
29 50 years old men. Choose between 2 alternatives: 1-Do not accept and stay in the current state = accept and you can have: better state = with p or worse state = with 1-p Time-Trade-Off Health i Health y X T Life duration (years) Health y = current health state Health i = health state with better quality of life but shorter duration
30 50 years old men. Choose between 2 alternatives: 1-Current state for the next 35 years = Better state = until death in 35-x years Discrete Choice Experiment
31 Discrete Choice Experiment Choice-based method The individual chooses between alternatives By sacrifying the benefit of something, he/she will have the benefit from the alternative at his/her disposal By making this choice, the individual gives his/her own value to the good/service and its characteristics DCE Based on Lancaster s theory: a good is a set of attributes and the value of the good is a function of each attribute of the good; Based on random utility theory, consistent with the neoclassic economic theory
32 DCE Based on Lancaster s theory: a good is a set of attributes and the value of the good is a function of each attribute of the good*; Based on random utility theory, consistent with the neoclassic economic theory * Lancaster, 1966 Perceived viral safety Risk of inhibitor development Factor infusion frequency on prophylaxis Pharmaceutical dosage form Distribution modes Price Characteristics and levels Attributes Mantovani et al, Haemophilia, 2005 Levels Second generation recombinant factors Very highly purified plasma derived factors Current (1/4 in PUPs) Reduced (1/6 in PUPs) Very reduced (1/10 in PUPs) Thrice a week Twice a week Once a week Lyophilized material for reconstitution Ready-to-use solution Home delivery Community pharmacy Hospital/Local Health Unit 650 for 1000 UI (plasma-derived) 929 for 1000 UI (Second generation recomb fact) 1115 for 1000 UI (+20% of 929)
33 DC model Based on Lancaster s theory: a good is a set of attributes and the value of the good is a function of each attribute of the good; Based on random utility theory*, consistent with the neoclassic economic theory* * Thurstone, 1927, McFadden, 1973; Manski, 1977
34 Neoclassical economic theory Assumption: the decision-maker is able to compare some alternatives (choice set) using a preference-indifference operator > Using the > operator is equivalent to assigning a value (utility) to each alternative and selecting the alternative with the highest utility Limitation: the human behavior is complex and a choice model should explicitly capture some level of uncertainty. Random utility theory Assumes, as the neoclassical economic theory, that the decision-maker has a perfect discrimination capability. Anyway the analist is supposed to have incomplete information: uncertainty is taken into account The utility is modeled as a random variable, in order to reflect this uncertainty i = decision-maker index j and k = alternatives to be compared, j the one to be chosen
35 Random utility model U ij = V ij + ε ij P ij = Prob (U ij > U ik ) = = Prob (V ij + ε ij > V ik + ε ik ) = = Prob (V ij -V ik > ε ij - ε ik ) j k P(j a, b,, n) = exp V j / Σ k exp V k i = decision-maker index j = the chosen alternative over k alternatives a, b,,n = k alternatives Perceived viral safety Risk of inhibitor development Factor infusion frequency on prophylaxis Pharmaceutical dosage form Distribution modes Price Characteristics and levels Attributes Mantovani et al, Haemophilia, 2005 Levels Second generation recombinant factors Very highly purified plasma derived factors Current (1/4 in PUPs) Reduced (1/6 in PUPs) Very reduced (1/10 in PUPs) Thrice a week Twice a week Once a week Lyophilized material for reconstitution Ready-to-use solution Home delivery Community pharmacy Hospital/Local Health Unit 650 for 1000 UI (plasma-derived) 929 for 1000 UI (Second generation recomb fact) 1115 for 1000 UI (+20% of 929)
36 Choice set DCE: Useful to estimate - α ij = alternative specific constant -X ij = attributes - taste weights = β V ij = α ij + βx ij Whether an attribute is important Relative importance of attributes marginal rates of substitution of attribute n over attribute n+1 (β n /β n+1 ) willingness to pay (WTP) for an attribute (β n /-β price ) willingness to give up time (β n /-β time ) Welfare/benefit (utility) scores
37 Milano, 15 novembre 2005 Milano, 15 novembre 2005
38 Uses and utilities of HRQoL instruments Clinical practice to understand something more about the individuals (patients ) health Uses and utilities of HRQoL instruments Clinical practice to understand something more about the individuals (patients ) health Population based studies to understand the impact of diseases, interventions
39 Uses and utilities of HRQoL instruments Clinical practice to understand something more about the individuals (patients ) health Population based studies to understand the impact of diseases, interventions Economic Evaluations to understand how to more efficiently allocate the available resouces Key elements on HRQoL evaluation
40 Key elements on HRQoL evaluation NO Gold Standard Compromise and choises according to aims, resources Battery
Qualità della Vita Legata allo Stato di Salute in Farmacoeconomia
Qualità della Vita Legata allo Stato di Salute in Farmacoeconomia Luciana Scalone, PharmD, DSc Centro di Farmacoeconomia Università degli Studi di Milano Problem Needs are unlimited resources are limited
More informationIntroduction to Pharmacoeconomics. Almut G. Winterstein, Ph.D.
Introduction to Pharmacoeconomics Almut G. Winterstein, Ph.D. Why do we need Health Economics? Suppose you are comparing two drugs or services where one is more expensive than the other. In choosing the
More informationOverview of Pharmaco- Economics Methodologies Maher Hassoun, M.S.
Overview of Pharmaco- Economics Methodologies Maher Hassoun, M.S. Director of Communications, ISPOR Lebanon Chapter (LSPOR) ISPOR Member Country Manager, Mundipharma Lebanon and Jordan Outline Current
More informationIntroduction of Health Economics
Introduction of Health Economics Prof. Jie Chen Health Technology Assessment & Research Center Fu Dan University 4 th March, 2004 Outline Why economics for healthcare services? Some basic economic concepts
More informationEconomic Evaluation of Health Care
Economic Evaluation of Health Care (Evaluasi Ekonomi untuk Pelayanan Kesehatan) Getting the best value for health spending Prof. dr. Bhisma Murti, MPH, MSC, PhD Institute of Health Economic and Policy
More informationASAP Regional Training on Epidemiological and Economic Tools for HIV/AIDS Strategic Planning S P ECONOMIC EVALUATION IN HEALTH CARE
ASAP Regional Training on Epidemiological and Economic Tools for HIV/AIDS Strategic Planning ECONOMIC EVALUATION IN HEALTH CARE Outline of the Session 1. What is Economic Evaluation? 2. Why do Economic
More informationPOLISH GUIDELINES FOR CONDUCTING PHARMACOECONOMIC EVALUATIONS. (project)
POLISH GUIDELINES FOR CONDUCTING PHARMACOECONOMIC EVALUATIONS Ewa Orlewska 1, Piotr Mierzejewski 1,2 (project) 1 Department of Experimental and Clinical Pharmacology, Medical University of Warsaw Head
More informationValuing EQ-5D-3L health states
Adding Value to EQ-5D-3L Valuation Studies: Taking Stock/Reviewing Options Moderator: Prof. Paul Kind, Centre for Health Economics, Management and Policy, HSE University, ST. Petersburg, Russia Discussion
More informationEconomic Evaluation: Making the case for diabetes selfmanagement
Economic Evaluation: Making the case for diabetes selfmanagement education NACDD Webinar Series Session 2: Applying Economic Evaluation October 4, 2012 Carsten Baumann, MA DSME Webinar Series Blueprint
More informationASAP Regional Training on Epidemiological and Economic Tools for HIV/AIDS Strategic Planning S P ECONOMIC EVALUATION IN HEALTH CARE
ASAP Regional Training on Epidemiological and Economic Tools for HIV/AIDS Strategic Planning ECONOMIC EVALUATION IN HEALTH CARE Outline of the Session 1. What is Economic Evaluation? 2. Why do Economic
More informationThe Use of Pharmacoeconomic Principles in Local Drug Policy Decisions in Poland
The Use of Pharmacoeconomic Principles in Local Drug Policy Decisions in Poland Prof. Karina Jahnz-Różyk Dr Joanna Lis ISPOR 16th Annual European Congress Dublin Ireland Pharmacoeconomics is formally stated
More informationEconomic Evaluations in Health An introduction for clinicians, researchers, and policy makers
Economic Evaluations in Health An introduction for clinicians, researchers, and policy makers Philip Leonard, PhD, MSSU and UNB Economics May 16, 2016 Saint John Regional Hospital, NB Economics in health
More informationAN OVERVIEW OF PHARMACOECONOMICS AND OUTCOMES RESEARCH
Int. J. LifeSc. Bt & Pharm. Res. 2012 Harika Javangula, 2012 Review Article ISSN XXXX-XXXX www.ijlbpr.com Vol.1, Issue. 1, January 2012 2012 IJLBPR. All Rights Reserved AN OVERVIEW OF PHARMACOECONOMICS
More informationStep by step guide to economic evaluation in cancer trials
What is CREST? The Centre for Health Economics Research and Evaluation (CHERE) at UTS has been contracted by Cancer Australia to establish a dedicated Cancer Research Economics Support Team (CREST) to
More informationFaculty of Medicine Health Economics and Policies ( ) The value of health. Hatim Jaber MD MPH JBCM PhD
Faculty of Medicine Health Economics and Policies (31505391) The value of health By Hatim Jaber MD MPH JBCM PhD 31-01-2018 Introduction to course 31505391(cont..) Course Content Week 1 Introduction to
More informationEfficiency: Concepts and Methods. Hui Ru Chang Department of Medical Affairs, Mackay Memorial Hospital May 25, 2010
Efficiency: Concepts and Methods Hui Ru Chang Department of Medical Affairs, Mackay Memorial Hospital May 25, 2010 1 Contents 2 What is Efficiency? Methods of Assessing Efficiency Cost Effectiveness Analysis
More informationWhat can Health Economics do for you?
Incorporating Health Economics into Grant Proposals Health Economics Short Course For more information and course dates, please visit our website: http://go.unimelb.edu.au/i8ba Or email us: health-economics@unimelb.edu.au
More informationReimbursement of Oncology Drugs in Saudi Arabia
Reimbursement of Oncology Drugs in Saudi Arabia Abdulaziz Al-Saggabi, B.Sc., M.Sc., Pharm.D. Director, Drug Policy & Economics Center Ministry of National Guard Health Affairs Chairman, ISPOR Arabic Network
More informationPIP DATA FOR MARKET ACCESS
PIP DATA FOR MARKET ACCESS By Mark Nuijten, PhD, MD, MBA Maart 13, 2012 London, UK GENERAL TRENDS IN HEALTH CARE SYSTEMS IN EUROPE Health Care Systems Budget Constraints Inceasing demand for health care
More informationHTA and Submissions. Ferg Mills, Angela Rocchi April 5, Agenda
HTA and Submissions Ferg Mills, Angela Rocchi April 5, 2017 Agenda The Decision Problem Role of HTA bodies in Canada CADTH, pcodr and INESSS Overview of the elements of the HTA submission Clinical package
More informationIntroduction to Health Economics. Educational Seminar ISPOR Dubai - September 19, 2018
Introduction to Health Economics Educational Seminar ISPOR Dubai - September 19, 2018 Introduction to health economics Part 1 Nancy Devlin Director of Research, Office of Health Economics, London ISPOR
More informationEconomics Concepts Overview
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this
More informationEconomics 317 Health Economics III Sample questions for midterm examination I February, 2011
University of Victoria Department of Economics Economics 317 Health Economics III Sample questions for midterm examination I February, 2011 1 Multiple guess questions. 1. The RAND Health Insurance Experiment
More informationIncorporating Economic Evaluation in Clinical & Translation Research. Setting expectations. Why bother with economic evaluation? Introduction 10/9/17
Incorporating Economic Evaluation in Clinical & Translation Research Fernando A. Wilson, PhD Health Services Research & Administration College of Public Health University of Nebraska Medical Center Setting
More informationEconomics 318 Health Economics. Midterm Examination II March 21, 2013 ANSWER KEY
University of Victoria Department of Economics Economics 318 Health Economics Instructor: Chris Auld Midterm Examination II March 21, 2013 ANSWER KEY Instructions. Answer all questions. For multiple choice
More informationCost-benefit analysis of first-generation antihistamines in the treatment of allergic rhinitis Sullivan P W, Follin S L, Nichol M B
Cost-benefit analysis of first-generation antihistamines in the treatment of allergic rhinitis Sullivan P W, Follin S L, Nichol M B Record Status This is a critical abstract of an economic evaluation that
More informationCost-Effectiveness Analysis: The Bare Essentials
Cost-Effectiveness Analysis: The Bare Essentials Michael K. Gould, MD, MS Director for Health Services Research and Implementation Science Department of Research and Evaluation Kaiser Permanente Southern
More informationECONOMIC VALUE OF VACCINES
ECONOMIC VALUE OF VACCINES ISPOR Forum of the Economic Value Assessment of Vaccines Designed to Prevent Infectious Disease Task Force Monday, May 23, 2016 Outline for the Forum Task Force Leadership Group
More informationModelling and Health Economics
EACS HIV Summer School 2018 Modelling and Health Economics Valentina Cambiano UCL Institute of Global Health 1 st September 2018 Conflict of Interests No conflict of interests to declare. 2 Outline What
More informationOnline Resource. Journal Quality of Life Research 2010, doi /s x.
Online Resource Title Population health status in China: EQ-5D results, by age, sex and socio-economic status, from the National Health Services Survey 2008 Journal Quality of Life Research 2010, doi 10.1007/s11136-010-9762-x.
More informationDiscounting in Economic Evaluation
Discounting in Economic Evaluation Henry A. Glick, Ph.D. Pharmacoeconomics March 26, 2012 www.uphs.upenn.edu/dgimhsr Which Lottery? Suppose you decided to buy a single lottery ticket You have a choice
More informationMedical Expenditure in Japan
The Pilot HTA Program in Japan ISPOR Asia Pacific Conference IP11: A Trial HTA Introduction in Japan: Learning and Way Forward 2018.9.10 Takashi Fukuda, PhD Director Center for Outcomes Research and Economic
More informationBayesian Analysis: Bayesian Analysis in Health Economics Bayesian Analysis: Posterior Interval Bayesian Analysis: Prior Distribution
Bayesian Analysis Bayesian Analysis Bayesian Analysis Bayesian Analysis Biotechnology Biotechnology Biotechnology Bootstrapping Case Mix Index Clinical Practice Guidelines Study Bias Study Bias Study Bias
More informationWhy Are We Here? A Quick Review of Valuation Methods
Willingness to Pay, Ability to Pay, and Money-Equivalent Benefit: Measuring And Using Monetized Health Benefits ISPOR Educational Symposium Why Are We Here? A Quick Review of Valuation Methods Richard
More informationrff report Valuing Health Outcomes: Policy Choices and Technical Issues Executive Summary Alan J. Krupnick MARCH 2004
rff report MARCH 2004 Valuing Health Outcomes: Policy Choices and Technical Issues Executive Summary Alan J. Krupnick MISSION Resources for the Future improves environmental and natural resource policymaking
More informationLecture 21: Logit Models for Multinomial Responses Continued
Lecture 21: Logit Models for Multinomial Responses Continued Dipankar Bandyopadhyay, Ph.D. BMTRY 711: Analysis of Categorical Data Spring 2011 Division of Biostatistics and Epidemiology Medical University
More informationChapter 3 PREFERENCES AND UTILITY. Copyright 2005 by South-Western, a division of Thomson Learning. All rights reserved.
Chapter 3 PREFERENCES AND UTILITY Copyright 2005 by South-Western, a division of Thomson Learning. All rights reserved. 1 Axioms of Rational Choice ( 理性选择公理 ) Completeness ( 完备性 ) if A and B are any two
More informationTOWARDS ESTIMATING THE IMPACT OF INTANGIBLE COST OF ILLNESS ON GDP: END- STAGE RENAL DISEASE IN TRINIDAD AND
TOWARDS ESTIMATING THE IMPACT OF INTANGIBLE COST OF ILLNESS ON GDP: END- STAGE RENAL DISEASE IN TRINIDAD AND Conference on the Economy October 9, 2015 TOBAGO 1 INTRODUCTION Intangible costs refer to the
More informationHealth financing in Thailand Issues for discussion
Health financing in Thailand Issues for discussion NESDB Workshop 11 September 2009 Toomas Palu, Lead Health Specialist Health and health financing in Thailand an international success story Good health
More informationTECHNICAL APPENDIX 1 THE FUTURE ELDERLY MODEL
TECHNICAL APPENDIX 1 THE FUTURE ELDERLY MODEL To estimate the potential health benefits of PCSK9 inhibitors, we use the Future Elderly Model (FEM), a dynamic microsimulation model developed by Goldman
More informationCRS Report for Congress Received through the CRS Web
CRS Report for Congress Received through the CRS Web Order Code RS22059 February 18, 2005 The Pros and Cons of Allowing the Federal Government to Negotiate Prescription Drug Prices Summary Jim Hahn Analyst
More informationRetirement and Unexpected Health Shocks
Retirement and Unexpected Health Shocks BÉNÉDICTE APOUEY (PSE, FRANCE) CAHIT GUVEN (DEAKIN UNIVERSITY, AUSTRALIA) CLAUDIA SENIK (PSE, FRANCE) Motivation Workers plan to retire as soon as they are entitled
More informationValue Assessment Frameworks: How Can They Meet The Challenge?
Page 1 of 5 Value Assessment Frameworks: How Can They Meet The Challenge? Robert Dubois, Kimberly Westrich, et al. March 2, 2017 Rising health care costs and pharmaceutical prices in particular are among
More informationA decision-analytic approach for supporting healthcare resource allocation
A decision-analytic approach for supporting healthcare resource allocation, Yrjänä Hynninen, and Ahti Salo Aalto University School of Business, Department of Information and Service Economy Aalti University
More informationProf. Francesco Saverio Mennini
Not reimburasable A STRUCTURED DEBATE REGARDING THE NATIONAL HEALTH ECONOMICS GUIDELINES IN SOUTHERN EUROPE Pharmaceutical Regulation and PhEconomics Guidelines in Italy Prof. Francesco Saverio Mennini
More informationMoral Hazard. Question for this section. Quick review of demand curves. ECON Fall 2007
Moral Hazard ECON 40565 Fall 2007 First day of class, listed five unique characteristics of the health care sector Uncertainty Large role for federal govt Agency problem Non-profit sector Medical care
More informationHEALTH CARE SYSTEM IN CROATIA
HEALTH CARE SYSTEM IN CROATIA Professor Miroslav Mastilica Andrija Štampar School of Public Health University of Zagreb mmastil@snz.hr Vanesa Benković, MA Public Health Leadership and Management vanesa@mediametar.hr
More informationHSPM 818: Economic Evaluation and Policy Analysis of Health Services. Fall Semester 2011, Week 1: Introduction Assistant Professor Brian Chen
HSPM 818: Economic Evaluation and Policy Analysis of Health Services Fall Semester 2011, Week 1: Introduction Assistant Professor Brian Chen Introductions Course description Course objective Assignments
More informationHEALTH CARE CHAPTER 22. Tuesday, September 27, 11
HEALTH CARE CHAPTER 22 YOU ARE HERE 2 WHY HEALTH CARE IS NOT JUST ANOTHER GOOD 3 WHY HEALTH CARE IS NOT JUST ANOTHER GOOD Rapid increases in quality (which get confused as price increases) Treatments developed
More informationThe Value of Preventable Injury Fatality (VPF) in New Zealand:
The Value of Preventable Injury Fatality (VPF) in New Zealand: Do we need a new VPF study? Presenter: Dr John Wren Principal Research Advisor ACC Research Presentation for New Zealand Association of Economists
More informationCan Happiness Data Help Evaluate Economic Policies?
Can Happiness Data Help Evaluate Economic Policies? Robert MacCulloch Matthew Abel Chair of Economics Graduate School of Management Auckland University Business School Presentation to the NZ Treasury 17
More informationDo Novel Value Measures Have a Place in European HTA?: A U.S. Health Economist Perspective
Do Novel Value Measures Have a Place in European HTA?: A U.S. Health Economist Perspective ISPOR-EU panel presentation, Monday Nov 12, 2018, 3.45-4.45pm [Breakout Session #2 (IP6)] November 12, 2018 Barcelona
More informationSocial preferences I and II
Social preferences I and II Martin Kocher University of Munich Course in Behavioral and Experimental Economics Motivation - De gustibus non est disputandum. (Stigler and Becker, 1977) - De gustibus non
More informationICER Value Assessment Framework: 1.0 to 2.0
ICER Value Assessment Framework: 1.0 to 2.0 Outline Background on ICER Version 1.0 development Conceptual basis for ICER value assessment framework Domains of value Long-term perspective (value for money)
More informationTIME VALUE OF MONEY AND DISCOUNTING IN ISLAMIC PERSPECTIVE. Islamic Research and Training Institute Islamic Development Bank, Jeddah.
Review of Islamic Economics, Vol. 1, No. 2 (1991). pp. 35-45 TIME VALUE OF MONEY AND DISCOUNTING IN ISLAMIC PERSPECTIVE M. Fahim Khan Islamic Research and Training Institute Islamic Development Bank, Jeddah.
More informationModerator: J van Loon,MSc Mapi. Advisor to the President, Head of International Affairs, HAS France
Comparing the challenges of comparative effectiveness Research in France, Italy and the Netherlands Current Situation and Perspectives Issue Panelists: F. Meyer, MD Advisor to President, France E. Xoxi,
More information1. Introduction. M. Yasodha 1, Dr. G. Ravindran 2
Savings and Investment Pattern of Teachers Working in Arts and Science Colleges in Coimbatore District M. Yasodha 1, Dr. G. Ravindran 2 1 Full Time Research scholar in Commerce, PG & Research Department
More informationPreferences and Utility
Preferences and Utility PowerPoint Slides prepared by: Andreea CHIRITESCU Eastern Illinois University 1 Axioms of Rational Choice Completeness If A and B are any two situations, an individual can always
More informationMACROECONOMICS. N. Gregory Mankiw. Unemployment 8/15/2011. In this chapter, you will learn: Natural rate of unemployment.
Percent of labor force 0 1 0 U P D A T E S E V E N T H E D I T I O N /15/011 MACROECONOMICS N. Gregory Mankiw PowerPoint Slides by Ron Cronovich C H A P T E R In this chapter, you will learn: about the
More informationRecommendations of the Panel on Cost- Effectiveness in Health and Medicine
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this
More informationGlossary. Chapter 7 Individual-level drug utilization analyses. Chapter 8 Measurement of drug expenditure
Glossary Chapter 7 Individual-level drug utilization analyses Incidence rate Used in epidemiology to express the rate of newly diseased in a population. For example, the incidence rate of insulin use is
More informationOptimal Risk Adjustment. Jacob Glazer Professor Tel Aviv University. Thomas G. McGuire Professor Harvard University. Contact information:
February 8, 2005 Optimal Risk Adjustment Jacob Glazer Professor Tel Aviv University Thomas G. McGuire Professor Harvard University Contact information: Thomas G. McGuire Harvard Medical School Department
More informationWhat does the Value of Modern Medicine Say About
What does the Value of Modern Medicine Say About the $50,000/QALY Threshold? Duke/NUS Singapore September 5, 2016 Mark S. Roberts, MD, MPP Professor and Chair, Department of Health Policy and Management
More informationPrescription Medicines: Costs in Context. Updated August 2016
Prescription Medicines: Costs in Context Updated August 2016 Medicines are Transforming the Treatment OF DEVASTATING DISEASES HEPATITIS C The leading cause of liver transplants and the reason liver cancer
More informationEconomic evaluations are defined as the comparative analysis of alternative
Nyman Economic Evaluations in Healthcare: Overview, Policy, and Uses John A. Nyman, PhD Overview: The Basics Economic evaluations are defined as the comparative analysis of alternative courses of action
More informationFiscal Implications of Chronic Diseases. Peter S. Heller SAIS, Johns Hopkins University November 23, 2009
Fiscal Implications of Chronic Diseases Peter S. Heller SAIS, Johns Hopkins University November 23, 2009 Defining Chronic Diseases of Concern Cancers Diabetes Cardiovascular diseases Mental Dementia (Alzheimers
More informationQALYs Versus WTP. James K. Hammitt
Risk Analysis, Vol. 22, No. 5, 2002 QALYs Versus WTP James K. Hammitt Quality adjusted life years (QALYs) and willingness to pay (WTP) are alternative measures of the value of reductions in health risk
More informationUC Berkeley Haas School of Business Economic Analysis for Business Decisions (EWMBA 201A) Fall Module I
UC Berkeley Haas School of Business Economic Analysis for Business Decisions (EWMBA 201A) Fall 2016 Module I The consumers Decision making under certainty (PR 3.1-3.4) Decision making under uncertainty
More information6/16/2008. Unemployment. In this chapter, you will learn. Assumptions: Natural rate of unemployment. A first model of the natural rate
C H A P T E R Unemployment In this chapter, you will learn about the natural rate of unemployment: what it means what causes it understanding its behavior in the real world slide 1 Natural rate of unemployment
More informationBEEM109 Experimental Economics and Finance
University of Exeter Recap Last class we looked at the axioms of expected utility, which defined a rational agent as proposed by von Neumann and Morgenstern. We then proceeded to look at empirical evidence
More informationGH SPC Model Solutions Spring 2014
GH SPC Model Solutions Spring 2014 1. Learning Objectives: 1. The candidate will understand pricing, risk management, and reserving for individual long duration health contracts such as Disability Income,
More informationLindsey Imada, PharmD Candidate 2016 Midwestern University, Chicago College of Pharmacy
Lindsey Imada, PharmD Candidate 2016 Midwestern University, Chicago College of Pharmacy Under the Preceptorship of Dr. Craig Stern Pro Pharma Pharmaceutical Consultants, Inc. September 11, 2015 S OBJECTIVES
More informationThe economics of health inequalities in the English NHS. Miqdad Asaria
The economics of health inequalities in the English NHS Miqdad Asaria m.asaria@lse.ac.uk Overview 1) Introduction 2) Cost of inequality 3) Inequality indicators 4) Distributional CEA 5) Conclusion Miqdad
More informationSocial Impact Bonds: Key Implementation Issues
Social Impact Bonds: Key Implementation Issues P. Mitchell Downey The Urban Institute November 16, 2011 American Society of Criminology Washington, D.C. John K. Roman, PhD The Urban Institute The views
More informationEmpirical Approaches in Public Finance. Hilary Hoynes EC230. Outline of Lecture:
Lecture: Empirical Approaches in Public Finance Hilary Hoynes hwhoynes@ucdavis.edu EC230 Outline of Lecture: 1. Statement of canonical problem a. Challenges for causal identification 2. Non-experimental
More informationA MODIFIED MULTINOMIAL LOGIT MODEL OF ROUTE CHOICE FOR DRIVERS USING THE TRANSPORTATION INFORMATION SYSTEM
A MODIFIED MULTINOMIAL LOGIT MODEL OF ROUTE CHOICE FOR DRIVERS USING THE TRANSPORTATION INFORMATION SYSTEM Hing-Po Lo and Wendy S P Lam Department of Management Sciences City University of Hong ong EXTENDED
More informationDemonstrating Value of Medicines Through Health Economic and Outcomes Evidence
Demonstrating Value of Medicines Through Health Economic and Outcomes Evidence Eleni Samaras Allen, PharmD March 22, 2016 Kissimmee, FL Disclaimer The views and opinions expressed in the following PowerPoint
More informationChapter 7 Unemployment and the Labor Market
Chapter 7 Unemployment and the Labor Market Modified by Yun Wang Eco 3203 Intermediate Macroeconomics Florida International University Summer 2017 2016 Worth Publishers, all rights reserved In this chapter,
More informationHealthcare in Europe and in the USA
Healthcare in Europe and in the USA 6 th edition: graphics - main results September 28 th 2012 1 In 2006, Europ Assistance Group and the Cercle Santé Société set up together with CSA Institute an European
More information{ } Sample Size and Power for the Comparison of Cost and Effect. Goal of Sample Size Calculation. Sample Size Formula, Common SDs.
Sample Size and Power for the Comparison of Cost and Effect Henry Glick Applications of Statistical Considerations in Health Economic Evaluations ISPOR 13 th International Meeting May 4, 2008 Goal of Sample
More informationUC Berkeley Haas School of Business Economic Analysis for Business Decisions (EWMBA 201A) Fall Module I
UC Berkeley Haas School of Business Economic Analysis for Business Decisions (EWMBA 201A) Fall 2018 Module I The consumers Decision making under certainty (PR 3.1-3.4) Decision making under uncertainty
More informationSTA2601. Tutorial letter 105/2/2018. Applied Statistics II. Semester 2. Department of Statistics STA2601/105/2/2018 TRIAL EXAMINATION PAPER
STA2601/105/2/2018 Tutorial letter 105/2/2018 Applied Statistics II STA2601 Semester 2 Department of Statistics TRIAL EXAMINATION PAPER Define tomorrow. university of south africa Dear Student Congratulations
More informationUS Reimbursement Systems: Effects on R&D
US Reimbursement Systems: Effects on R&D Patricia M. Danzon, PhD Professor Emeritus The Wharton School University of Pennsylvania Theory: Optimal Reimbursement Rules to Create Efficient R&D Incentives
More informationDO YOU SPEAK MEDICARE PART D?
CMA WEEKLY ALERT JULY 21, 2005 DO YOU SPEAK MEDICARE PART D? In the next few months the older people and people with disabilities who rely on Medicare, along with their families, friends, and advocates,
More informationINTERNATIONAL METHODS GUIDELINES FOR ECONOMIC EVALUATION Where Are We Now? Michael Drummond Centre for Health Economics, University of York
INTERNATIONAL METHODS GUIDELINES FOR ECONOMIC EVALUATION Where Are We Now? Michael Drummond Centre for Health Economics, University of York Introduction Since the PBAC guidelines in 1992, many jurisdictions
More informationNational Centre for Pharmacoeconomics. Guidelines for Inclusion of Drug Costs in Pharmacoeconomic Evaluations
National Centre for Pharmacoeconomics Guidelines for Inclusion of Drug Costs in Pharmacoeconomic Evaluations Version 1.13 Please Note: This document may be updated periodically, therefore please refer
More informationPAYING FOR THE HEALTHCARE WE WANT
PAYING FOR THE HEALTHCARE WE WANT MARK STABILE 1 THE PROBLEM Well before the great recession of 2008, Canada s healthcare system was sending out signals that it had a financing problem. Healthcare costs
More informationREGULATORY REPORT CARD May 2015
AGENCY Department of Health and Human Services, Food and Drug Administration Rule title Focused Mitigation Strategies to Protect Food against Intentional Adulteration RIN 0910 AG6 Publication Date December
More informationGOVERNMENT PAPER. There are some signs that these views are changing with new generations.
Older people on the labour market in Iceland Public policy and measures within continuing education Gissur Pétursson Directorate of Labour 1. Conditions on the labour market Employment participation among
More informationBehavioral Economics. Student Presentations. Daniel Kahneman, Thinking, Fast and Slow
Student Presentations Daniel Kahneman, Thinking, Fast and Slow Chapter 26, Prospect Theory The main idea or concept of this chapter: Diminishing Sensitivity When people have different amounts of wealth,
More informationCapital Inflows: A Threat to Growth?
Capital Inflows: A Threat to Growth? David Backus, Thomas Cooley, and Espen Henriksen Restoring Growth in Advanced Economies NCAER, World Bank, & NYU October 7, 2010 This version: October 9, 2010 Backus,
More informationPUBLIC HEALTH PROGRAMME GUIDANCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE PUBLIC HEALTH PROGRAMME GUIDANCE SCOPE 1 Guidance title Guidance for primary care services and employers on the management of long-term sickness and
More informationRecent data (lag time is less than 6 months)
Centricity 2 GE Centricity is an electronic health record system that enables ambulatory care physicians and clinical staff to document patient encounters and exchange clinical data with other providers
More informationKnown unknowns and unknown unknowns: uncertainty from the decision-makers perspective. Neil Hawkins Oxford Outcomes
Known unknowns and unknown unknowns: uncertainty from the decision-makers perspective Neil Hawkins Oxford Outcomes Outline Uncertainty Decision making under uncertainty Role of sensitivity analysis Fundamental
More informationECON. CHAPTER The Art and. McEachern Micro. Science of Economic Analysis. Designed by Amy McGuire, B-books, Ltd.
Designed by Amy McGuire, B-books, Ltd. Micro ECON McEachern 2010-2011 1 CHAPTER The Art and Science of Economic Analysis Chapter 1 Copyright 2010 by South-Western, a division of Cengage Learning. All rights
More informationMicroeconomics II. CIDE, MsC Economics. List of Problems
Microeconomics II CIDE, MsC Economics List of Problems 1. There are three people, Amy (A), Bart (B) and Chris (C): A and B have hats. These three people are arranged in a room so that B can see everything
More informationLARC: Return on Investment Virtual Learning Session. August 2, :00-4:00p ET For Audio: , ext #
LARC: Return on Investment Virtual Learning Session August 2, 2016 2:00-4:00p ET For Audio: 866-740-1260, ext. 5273187# Agenda 2:00 Welcome and Introductions 2:10 Basics of Economic Analysis and Return
More informationIntroduction to Decision Analysis
Introduction to Decision Analysis M.Sc. (Tech) Yrjänä Hynninen Dept of Mathematics and Systems Analysis Analytics and Data Science seminar, October 16, 2017 Learning objectives Develop an understanding
More informationLarge tick assets: implicit spread and optimal tick value
Large tick assets: implicit spread and optimal tick value Khalil Dayri 1 and Mathieu Rosenbaum 2 1 Antares Technologies 2 University Pierre and Marie Curie (Paris 6) 15 February 2013 Khalil Dayri and Mathieu
More informationRisk adjustment is an important opportunity to ensure the sustainability of the exchanges and coverage for patients with chronic conditions.
RISK ADJUSTMENT Risk adjustment is an important opportunity to ensure the sustainability of the exchanges and coverage for patients with chronic conditions. If risk adjustment is not implemented correctly,
More information